Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes

Stephan R. BohlDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;

Anna DolnikDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;

Thomas JensenMedical Prognosis Institute (MPI), Hørsholm, Denmark;

Katharina M. LangDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;

Björn HackansonDepartment of Internal Medicine I, University of Freiburg Faculty of Medicine, Freiburg, Germany

Verena I. GaidzikDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;

Peter PaschkaDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;

Steen KnudsenMedical Prognosis Institute (MPI), Hørsholm, Denmark;

Konstanze DöhnerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;

Hartmut DöhnerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;

Rainer ClausDepartment of Internal Medicine I, University of Freiburg Faculty of Medicine, Freiburg, Germany

Michael LübbertDepartment of Internal Medicine I, University of Freiburg Faculty of Medicine, Freiburg, Germany

Lars BullingerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; Correspondence[email protected]

Your download is now in progress and you may close this window